Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Starting HBV Treatment in Pregnancy: Patient and Physician Sharing Session #1

In episode 1 of this ongoing series, listen to a conversation between Grace LH Wong, MD, and her patient, Ms. Chan, on the shared decision for Ms. Chan to start treatment for hepatitis B infection during her pregnancy.
Grace LH Wong, MD
Released: March 26, 2021

In this episode, Part 1 of an ongoing series of sharing sessions between a physician and patient, Grace LH Wong, MD, and her patient, Ms. Chan, discuss how they collaborated in care to reach a shared decision regarding HBV treatment initiation. The conversation focuses on how Ms. Chan felt about the decision to start therapy during her pregnancy and how Dr. Wong approaches shared decision-making with her patients regarding their HBV management.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Information on this Educational Activity

Faculty

Grace LH Wong, MD

Professor
Director, Medical Data Analytics Centre (MDAC)
Deputy Director, Center for Liver Health
Assistant Dean (Learning Experience), Faculty of Medicine
The Chinese University of Hong Kong
Honorary Consultant
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
Prince of Wales Hospital
Hong Kong

Grace LH Wong, MD, has disclosed that she has received consulting fees from Gilead Sciences and Janssen; fees for research support from AbbVie and Gilead Sciences; and fees for non-CME/CE services from Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen, and Roche.

Program Medium

This program has been made available online.

Related Content

Brief Clinical Care Options (CCO) presentation on APASL guidance on limitations of current HCC surveillance recommendations in chronic HBV infection

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: October 7, 2021 Expired: October 6, 2022

Takeshi Saito, MD, PhD, discusses the limitations of current approaches to treating HDV and looks ahead to new and emerging HDV therapies, from Clinical Care Options (CCO)

Takeshi Saito, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 28, 2021 Expired: September 27, 2022

Download key slides describing lessons learned in delivery of care from the COVID-19 pandemic worth carrying forward in the management of viral hepatitis.

Gregory Dore, MBBS, PhD, FRACP, MPH Stacey Trooskin, MD, PhD, MPH Released: September 23, 2021

Brief Clinical Care Options (CCO) presentation on using the EASL guidelines to determine treatment candidacy in patients with hepatitis B virus HBV.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 7, 2021 Expired: September 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue